Pharming Group (NASDAQ:PHAR) Shares Up 5% - Should You Buy?

Key Points

• Pharming Group's stock increased by 5% to $14.72, with trading volume lower than average at approximately 5,165 shares.
• The company reported earnings of $0.06 per share for the last quarter, significantly exceeding the consensus estimate of -$0.10.
• Silverberg Bernstein Capital Management LLC raised its stake in Pharming Group by 8.6%, indicating a growing institutional interest in the company.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares were up 5% on Wednesday . The stock traded as high as $14.50 and last traded at $14.72. Approximately 5,165 shares changed hands during trading, a decline of 19% from the average daily volume of 6,406 shares. The stock had previously closed at $14.01.

Pharming Group Trading Up 3.9%

The company has a debt-to-equity ratio of 0.38, a current ratio of 2.79 and a quick ratio of 2.07. The firm's fifty day moving average is $11.45 and its 200-day moving average is $10.07. The firm has a market cap of $997.37 million, a price-to-earnings ratio of -112.58 and a beta of 0.05.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.16. The firm had revenue of $93.20 million for the quarter, compared to analyst estimates of $70.36 million. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%. Pharming Group has set its FY 2025 guidance at EPS. Equities analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.08% of Pharming Group worth $557,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.